相关实验视频

Updated: Sep 11, 2025

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

患有COVID-19的90天以上的发烧婴儿存在严重细菌感染风险

Rufu Furuya¹, Shun Kishibe², Takahiro Itagaki³

¹Department of General Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, JPN.

|August 18, 2025

概括

患有COVID-19的90天以下发烧的婴儿与没有病毒的婴儿相比,严重细菌感染 (SBI) 的风险明显较低. 然而,尿路感染 (UTI) 仍然是一个问题,需要进行尿液分析.

科学领域:

儿科儿科儿科
传染性疾病传染性疾病
流行病学流行病学

背景情况:

在COVID-19发烧的婴儿中,严重细菌感染 (SBI) 的风险尚未完全理解,特别是在日本.
以前的研究表明,COVID-19阳性婴儿的SBI风险可能较低.

研究的目的:

为了比较患有SBI的发病率和临床特征,在患有COVID-19的和没有COVID-19的90天以上发烧的婴儿中进行SBI的发生率和临床特征.
调查COVID-19诊断的婴儿中特定类型的SBI.

主要方法:

对发烧婴儿 (≤90天) 访问日本儿童医院 (2021年4月至2022年11月) 的回顾性队列研究.
通过阳性PCR或密切接触定义的COVID-19组;非COVID-19组作为对照.
其中SBI包括尿路感染 (UTI),细菌性肺炎,细菌病和脑膜炎.

主要成果:

包括396名婴儿;125人在COVID-19组.
在COVID-19组中,SBI发生率为5.6%,而非COVID-19组为16.6% (p<0.05).
在COVID-19组中的所有SBI都是尿路感染;在呼吸道/胃肠道症状中没有显著差异.

结论:

在COVID-19阳性发烧婴儿中,SBI的发生率明显较低.
SBI,特别是尿路感染的风险不是可以忽视的,支持发烧的婴儿的尿液分析.
这些发现为了解COVID-19发烧婴儿SBI风险的理解增加了证据.

关键词:

在COVID-19中,有很多人.发烧的婴儿婴儿这是SARS-CoV-2病毒.他们是SBI.严重的细菌感染.尿路感染尿路感染需要使用的东西.

更多相关视频

Using Bioluminescent Imaging to Investigate Synergism Between Streptococcus pneumoniae and Influenza A Virus in Infant Mice

Using Bioluminescent Imaging to Investigate Synergism Between Streptococcus pneumoniae and Influenza A Virus in Infant Mice

Published on: April 14, 2011

Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat

Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat

Published on: October 29, 2014

相关概念视频

Factors Affecting the Risk of Infection

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...

Transmission-based Precautions I: Contact, Enteric, and Droplets

Transmission-based Precautions I: Contact, Enteric, and Droplets

Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...

Increased Body Temperature

Increased Body Temperature

A body temperature above 38°C (100.4 °F) is known as fever or pyrexia, and a person with fever is termed 'febrile.' Typically, the hypothalamus, a part of the brain that acts as the body's thermostat, regulates body temperature through a thermoregulatory setpoint. It receives signals from cold and warm thermal receptors throughout the body and adjusts the body's temperature accordingly. Fever occurs when this hypothalamic setpoint is altered, usually in...

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: